Equinix Inc vs IDEXX Laboratories, Inc. — how do they compare? Equinix Inc trades at $1,063.4 (market cap $101.87B), while IDEXX Laboratories, Inc. trades at $571.72 (market cap $46.22B). The key difference: Equinix Inc is far larger — about 2.2× IDEXX Laboratories, Inc.'s market cap, and Equinix Inc pays a 2% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| EQIX | IDXX | |
|---|---|---|
Market Cap | $101.87B | $46.22B |
Sector | Real Estate | Health |
52-Week High | $1.12K | $766.68 |
52-Week Low | $726.09 | $526.44 |
Enterprise Value | $123.00B | $47.12B |
Dividend Yield | 2% | — |
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,061.19, up 1.71% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing revenue expectations. Strong demand for AI infrastructure and record bookings support a raised long-term growth outlook. However, high valuation ratios, including a P/E of 66.44 and EV/EBITDA of 27.58, reflect premium pricing. Cash flow trends show significant capital expenditures, with net cash flow negative in 2025 and 2026.
The outlook for EQIX is cautiously optimistic, driven by AI-driven demand and strategic partnerships, but elevated debt levels and valuation multiples pose risks. Analyst consensus is strongly bullish with a $1,120 price target, though investors should monitor execution on growth targets and debt management amid competitive and macroeconomic pressures.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Trailing returns across standard periods
Latest headlines on both assets
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →